210 related articles for article (PubMed ID: 33583629)
21. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
22. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
[TBL] [Abstract][Full Text] [Related]
23. Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal cancer.
Motoori M; Yano M; Ishihara R; Yamamoto S; Kawaguchi Y; Tanaka K; Kishi K; Miyashiro I; Fujiwara Y; Shingai T; Noura S; Ohue M; Ohigashi H; Nakamura S; Ishikawa O
Ann Surg Oncol; 2012 Jul; 19(7):2135-41. PubMed ID: 22302264
[TBL] [Abstract][Full Text] [Related]
24. Comparison Between Esophagectomy and Definitive Chemoradiotherapy in Patients With Esophageal Cancer.
Wang BY; Hung WH; Wu SC; Chen HC; Huang CL; Lin CH; Chen HS
Ann Thorac Surg; 2019 Apr; 107(4):1060-1067. PubMed ID: 30571951
[TBL] [Abstract][Full Text] [Related]
25. A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer.
Yokota T; Kato K; Hamamoto Y; Tsubosa Y; Ogawa H; Ito Y; Hara H; Ura T; Kojima T; Chin K; Hironaka S; Kii T; Kojima Y; Akutsu Y; Matsushita H; Kawakami K; Mori K; Makiuchi T; Nagumo R; Kitagawa Y
Ann Surg Oncol; 2020 Feb; 27(2):460-467. PubMed ID: 31376034
[TBL] [Abstract][Full Text] [Related]
26. Trends in treatment and overall survival among patients with proximal esophageal cancer.
de Vos-Geelen J; Geurts SM; van Putten M; Valkenburg-van Iersel LB; Grabsch HI; Haj Mohammad N; Hoebers FJ; Hoge CV; Jeene PM; de Jong EJ; van Laarhoven HW; Rozema T; Slingerland M; Tjan-Heijnen VC; Nieuwenhuijzen GA; Lemmens VE
World J Gastroenterol; 2019 Dec; 25(47):6835-6846. PubMed ID: 31885424
[TBL] [Abstract][Full Text] [Related]
27. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials.
Oppedijk V; van der Gaast A; van Lanschot JJ; van Hagen P; van Os R; van Rij CM; van der Sangen MJ; Beukema JC; Rütten H; Spruit PH; Reinders JG; Richel DJ; van Berge Henegouwen MI; Hulshof MC
J Clin Oncol; 2014 Feb; 32(5):385-91. PubMed ID: 24419108
[TBL] [Abstract][Full Text] [Related]
28. TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.
Bando H; Kotani D; Tsushima T; Hara H; Kadowaki S; Kato K; Chin K; Yamaguchi K; Kageyama SI; Hojo H; Nakamura M; Tachibana H; Wakabayashi M; Fukutani M; Togashi Y; Fuse N; Nishikawa H; Kojima T
BMC Cancer; 2020 Apr; 20(1):336. PubMed ID: 32312286
[TBL] [Abstract][Full Text] [Related]
29. A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246.
Swisher SG; Winter KA; Komaki RU; Ajani JA; Wu TT; Hofstetter WL; Konski AA; Willett CG
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1967-72. PubMed ID: 21507583
[TBL] [Abstract][Full Text] [Related]
30. Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma.
Kumabe A; Fukada J; Kota R; Koike N; Shiraishi Y; Seki S; Yoshida K; Kitagawa Y; Shigematsu N
Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29228166
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
Koo DH; Park SI; Kim YH; Kim JH; Jung HY; Lee GH; Choi KD; Song HJ; Song HY; Shin JH; Cho KJ; Yoon DH; Kim SB
Cancer Chemother Pharmacol; 2012 Mar; 69(3):655-63. PubMed ID: 21968953
[TBL] [Abstract][Full Text] [Related]
32. Salvage radiation therapy and chemoradiation therapy for postoperative locoregional recurrence of esophageal cancer.
Kobayashi R; Yamashita H; Okuma K; Shiraishi K; Ohtomo K; Nakagawa K
Dis Esophagus; 2014 Jan; 27(1):72-8. PubMed ID: 23551708
[TBL] [Abstract][Full Text] [Related]
33. Salvage Endoscopic Argon Plasma Coagulation After Chemoradiotherapy for Inoperable Esophageal Cancer.
Matsutani T; Nomura T; Hagiwara N; Matsuda A; Uchida E
Surg Laparosc Endosc Percutan Tech; 2017 Oct; 27(5):384-390. PubMed ID: 28727635
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant chemotherapy does not benefit patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.
Chen M; Shen M; Lin Y; Liu P; Liu X; Li X; Li A; Yang R; Ni W; Zhou X; Zhang L; Xu B; Lin J; Chen J; Tian Y
Radiat Oncol; 2018 Aug; 13(1):150. PubMed ID: 30111361
[TBL] [Abstract][Full Text] [Related]
35. Salvage concurrent radio-chemotherapy for post-operative local recurrence of squamous-cell esophageal cancer.
Zhang J; Peng F; Li N; Liu Y; Xu Y; Zhou L; Wang J; Zhu J; Huang M; Gong Y
Radiat Oncol; 2012 Jun; 7():93. PubMed ID: 22713587
[TBL] [Abstract][Full Text] [Related]
36. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma.
Barbetta A; Hsu M; Tan KS; Stefanova D; Herman K; Adusumilli PS; Bains MS; Bott MJ; Isbell JM; Janjigian YY; Ku GY; Park BJ; Wu AJ; Jones DR; Molena D
J Thorac Cardiovasc Surg; 2018 Jun; 155(6):2710-2721.e3. PubMed ID: 29548582
[TBL] [Abstract][Full Text] [Related]
37. Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma.
Zeng J; Cui X; Cheng L; Chen Y; Du X; Sheng L
Cancer Radiother; 2021 Jul; 25(5):441-446. PubMed ID: 33958272
[TBL] [Abstract][Full Text] [Related]
38. Definitive concurrent chemoradiotherapy with paclitaxel plus carboplatin is superior to cisplatin plus 5-fluorouracil in patients with inoperable esophageal squamous cell carcinoma using retrospective, real-world evidence.
Hsieh JC; Chiang PC; Hung TM; Chao YK; Kuo YC; Wen CT; Su PJ; Peng MT; Chen HW; Liu HL; Chang HK; Wu MH; Wang HM
Cancer Med; 2021 Dec; 10(23):8300-8309. PubMed ID: 34706159
[TBL] [Abstract][Full Text] [Related]
39. Definitive salvage radiation therapy and chemoradiation therapy for lymph node oligo-recurrence of esophageal cancer: a Japanese multi-institutional study of 237 patients.
Yamashita H; Jingu K; Niibe Y; Katsui K; Matsumoto T; Nishina T; Terahara A
Radiat Oncol; 2017 Feb; 12(1):38. PubMed ID: 28219406
[TBL] [Abstract][Full Text] [Related]
40. Endoscopic resection as an independent predictive factor of local control in patients with T1bN0M0 esophageal squamous cell carcinoma treated with chemoradiotherapy: a retrospective study.
Miyazaki T; Myojin M; Hosokawa M; Aoyama H; Okahara S; Takahashi H
Radiat Oncol; 2022 Jan; 17(1):11. PubMed ID: 35057830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
